Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
REPL 
Replimune Group Inc (REPL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: REPL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.86
1 Year Target Price $4.86
| 3 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.96% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 445.70M USD | Price to earnings Ratio - | 1Y Target Price 4.86 |
Price to earnings Ratio - | 1Y Target Price 4.86 | ||
Volume (30-day avg) 8 | Beta 0.51 | 52 Weeks Range 2.68 - 17.00 | Updated Date 09/17/2025 |
52 Weeks Range 2.68 - 17.00 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.45% | Return on Equity (TTM) -73.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 124930348 | Price to Sales(TTM) - |
Enterprise Value 124930348 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.24 | Shares Outstanding 78055846 | Shares Floating 49983061 |
Shares Outstanding 78055846 | Shares Floating 49983061 | ||
Percent Insiders 2 | Percent Institutions 104.94 |
Upturn AI SWOT
Replimune Group Inc
Company Overview
History and Background
Replimune Group Inc. was founded in 2015 and is focused on developing oncolytic immunotherapies. It emerged from research conducted at the University of Leeds and Massachusetts General Hospital, with the aim of creating a novel class of cancer treatments based on genetically modified viruses.
Core Business Areas
- Oncolytic Immunotherapies: Replimune develops oncolytic viruses designed to selectively replicate in and destroy tumor cells while also eliciting a systemic anti-tumor immune response.
Leadership and Structure
Philip Astrow serves as Chief Executive Officer. The company has a board of directors overseeing strategic decisions.
Top Products and Market Share
Key Offerings
- RP1 (vusolimogene oderparepvec): RP1 is Replimune's lead product candidate, an oncolytic virus immunotherapy targeting various solid tumors. Currently in Phase 2 and Phase 3 trials. Market share is currently near 0 as the drug is not yet approved. Key competitors include Amgen (AMGN) with Imlygic, and various checkpoint inhibitors from companies like Merck (MRK) and Bristol Myers Squibb (BMY).
- RP2 and RP3: These are next-generation oncolytic immunotherapy candidates with increased potency. They are in earlier stages of clinical development. Market share is currently near 0 as the drug is not yet approved. Competitors are similar to RP1.
Market Dynamics
Industry Overview
The oncolytic virus immunotherapy market is growing, driven by increasing cancer incidence and the need for novel treatment options. The market is competitive with several companies developing similar therapies.
Positioning
Replimune aims to be a leader in oncolytic immunotherapy, differentiating itself through its proprietary platform and the potential of its RP1 candidate to address a broad range of solid tumors.
Total Addressable Market (TAM)
The total addressable market for oncolytic virus immunotherapy is estimated to be in the billions of dollars. Replimune is positioned to capture a significant share if RP1 is successfully approved and commercialized.
Upturn SWOT Analysis
Strengths
- Novel oncolytic virus platform
- Promising clinical trial results for RP1
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical trial execution risks
- Regulatory approval uncertainty
- Reliance on a limited number of product candidates
- High cash burn rate
Opportunities
- Expanding RP1 to additional tumor types
- Partnering with larger pharmaceutical companies
- Developing next-generation oncolytic viruses
- Acquisition by a larger pharmaceutical company
Threats
- Competition from other oncolytic viruses and immunotherapies
- Unfavorable clinical trial results
- Regulatory setbacks
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- BMY
- VIRI
- ONCR
Competitive Landscape
Replimune is positioned competitively within the oncolytic virus immunotherapy market, with a focus on RP1's potential. They face competition from established pharmaceutical companies with checkpoint inhibitors, and other biotech firms with novel therapies.
Growth Trajectory and Initiatives
Historical Growth: Replimune's growth has been driven by advancements in its clinical programs and strategic partnerships.
Future Projections: Future growth is dependent on the successful development and commercialization of RP1 and other product candidates. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing RP1 through Phase 2 and Phase 3 trials, and expanding the pipeline with RP2 and RP3.
Summary
Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies, particularly RP1. While their novel platform shows promise, it's still in early-stage testing, making them a high risk high reward company. Successful clinical trials and regulatory approvals are critical for their future growth. Competition from larger pharmaceutical companies poses a significant challenge, and financial sustainability is reliant on continued funding or partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Replimune Group Inc. SEC Filings, Company Website, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share percentages are approximate and based on the analyst estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Replimune Group Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2018-07-20 | CEO & Director Dr. Sushil Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 479 | Website https://www.replimune.com |
Full time employees 479 | Website https://www.replimune.com | ||
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.